Table 1.
Summary of demographics, tumor-related variables, and treatment patterns for the utilization cohort; women and men with stage I-III breast cancer who underwent surgery and had adequate information for IHC-subtyping (BCBaSe 3.0/NKBC, 2008–2019)
| Factors | Female (N = 82,401), n (%) | Male (N = 487), n (%) | p value |
|---|---|---|---|
| Age in yrs, median (range) | 64 (19–99) | 69 (29–94) | < 0.001 |
| Calendar year at diagnosis | |||
| 2008–2011 | 22,001 (26.7) | 108 (22.2) | 0.026 |
| 2012–2015 | 26,780 (32.5) | 154 (21.6) | |
| 2016–2020 | 33,620 (40.8) | 225 (46.2) | |
| Education Level | |||
| Low ≦9 years | 17,330 (21.3) | 149 (30.8) | < 0.001 |
| Intermediate 10–12 years | 34,310 (42.1) | 200 (41.3) | |
| High ≧13 years | 29,790 (36.6) | 135 (27.9) | |
| Household Income | |||
| Q1 | 20,166 (24.6) | 114 (23.5) | 0.602 |
| Q2 | 20,792 (25.4) | 127 (26.2) | |
| Q3 | 20,545 (25.1) | 132 (27.2) | |
| Q4 | 20,383 (24.9) | 112 (23.1) | |
| Regions | |||
| Northern | 6822 (8.3) | 47 (9.7) | 0.519 |
| Stockholm-Gotland | 19,185 (23.4) | 99 (20.4) | |
| Uppsala-Örebro | 17,143 (20.9) | 102 (21.0) | |
| South | 12,965 (15.8) | 79 (16.3) | |
| Southeast | 8803 (10.7) | 48 (9.9) | |
| Western (Halland) | 17,142 (20.9) | 11 (22.8) | |
| Clinical T stage | |||
| T 0–1 | 54,155 (65.7) | 263 (54.0) | < 0.001 |
| T 2–4 | 27,893 (33.9) | 221 (45.4) | |
| Clinical N stage | |||
| cN + | 10,246 (12.4) | 108 (22.2) | < 0.001 |
| cN- | 71,881 (87.2) | 378 (77.6) | |
| Histological grade | |||
| Well differentiated (G1) | 16,013 (19.4) | 48 (9.9) | < 0.001 |
| Moderately differentiated (G2) | 40,137 (48.7) | 246 (50.5) | |
| Poorly differentiated (G3) | 21,346 (25.9) | 171 (35.1) | |
| Subtype according to IHC | |||
| Luminal | 63,728 (77.3) | 423 (86.9) | < 0.001 |
| Her2 positive | 11,059 (13.4) | 61 (12.5) | |
| TNBC | 7614 (9.2) | 3 (0.6) | |
| Morphological subtype | |||
| Ductal | 61,414 (79.1) | 429 (91.9) | < 0.001 |
| Lobular | 10,719 (13.8) | 7 (1.5) | |
| Other | 5503 (7.1) | 31 (7.0) | |
| Breast surgery | |||
| Breast conserving surgery | 49,891 (60.5) | 480 (98.6) | < 0.001 |
| Mastectomy | 32,510 (39.5) | 7 (1.5) | |
| Axillary surgery | |||
| Sentinel lymph node dissection (SLND) | 55,566 (70.2) | 265 (57.7) | < 0.001 |
| Axillary lymph node dissection (ALND) | 12,253 (15.5) | 113 (24.6) | |
| SLND = > ALND | 11,363 (14.4) | 81 (17.6) | |
| Adjuvant chemotherapy | |||
| Yes | 23,029 (27.9) | 163 (33.5) | 0.007 |
| No | 59,372 (72.1) | 324 (66.5) | |
| Adjuvant radiοtherapy | |||
| Yes | 50,513 (61.3) | 156 (32.0) | < 0.001 |
| No | 31,888 (38.7) | 331 (68.0) | |
| Adjuvant endocrine therapy | |||
| Yes | 53,368 (64.8) | 383 (78.6) | < 0.001 |
| No | 29,033 (35.2) | 104 (21.4) | |
| Neoadjuvant chemotherapy | |||
| Yes | 6463 (7.8) | 24 (4.9) | 0.017 |
| No | 75,938 (92.2) | 463 (95.1) |
Bold text indicates a statistically significant difference with a p-value less than 0.05